FDA approves milestone biosimilar insulin drug
29-07-2021
Medicure and Nexus agree Aggrastat generic licence
20-11-2020
Margarett24 / Shutterstock.com
Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Nexus, Nevakar, hypotension drug, Emerphed, patents, NDA, FDA
